Patients If GLP-1s work too well, what happens next for metabolic dis... What happens if GLP-1s work too well?
News Lilly's 'triple G' retatrutide aces crucial obesity trial Lilly's retatrutide achieved weight loss of more than 30% at two years in a new trial, firming up its credentials as a next-generation obesity drug.
Patients The cardio-renal-metabolic space and obesity as a chronic di... The podcast welcomes Dr Ramy Younes, corporate VP, global head of clinical development, cardiorenalmetabolism, at Boehringer Ingelheim.
News Lilly UK recruits ex-England cricketer as obesity champion Lilly UK's obesity champion Ashley Giles, who won the Ashes with England in 2005, is urging people struggling with their weight to ask for help.
News Novo, Lilly trade oral GLP-1 data readouts at ECO Novo Nordisk trumpets oral Wegovy efficacy data at ECO, while Lilly builds the case for switching to Foundayo in maintenance phase after injectables.
News Novo says high-dose Wegovy can cause 28% weight loss Novo Nordisk has built the case for migration to its 'triple-dose' version of injectable GLP-1 Wegovy with new weight-loss and body composition data.
Sales & Marketing Sponsored Are Insights leaders seeing real commercial value from AI ad... Day One Strategy’s second annual AI in Pharma State of Play report addresses the challenges Pharma Insights teams are facing as AI adoption continues.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
